Mizuho Securities Reaffirms Outperform Rating for Axsome Therapeutics, Sets $106 Price Target

☀️Trending News

Axsome Therapeutics ($NASDAQ:AXSM) is a biopharmaceutical company that focuses on developing novel therapies for the treatment of central nervous system (CNS) disorders. The company’s stock has been gaining attention from investors due to its potential breakthrough treatments and recent positive news from analysts. One such firm, Mizuho Securities, has reaffirmed its Outperform rating for Axsome Therapeutics and has set a price target of $106.00. Mizuho Securities is a leading global investment bank that provides financial and advisory services to its clients. The firm’s analysts closely follow the healthcare sector and have been closely monitoring Axsome Therapeutics’ progress. Their latest report reaffirms their belief in the company’s potential and highlights the positive outlook for its stock. This oral medication is being developed for the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD).

These candidates have shown promising results in clinical trials and have the potential to address unmet medical needs in their respective markets. The firm’s $106.00 price target also takes into account Axsome Therapeutics’ strong financial position. This gives the company a solid financial footing and reduces the risk for investors. With promising product candidates and a strong financial position, Axsome Therapeutics has positioned itself as a leader in the development of novel treatments for CNS disorders. Investors who share Mizuho Securities’ positive outlook may want to consider adding this stock to their portfolio.

Stock Price

This news comes after AXSOME THERAPEUTICS stock opened at $85.15 and closed at $83.54 on Wednesday, showing a decrease of 1.51% from the previous closing price of $84.82. It indicates that the firm believes the company will outperform the market and that its stock is undervalued. Additionally, setting a price target of $106 shows confidence in the potential growth of Axsome Therapeutics‘ stock. This news may come as a relief to investors who have seen a slight dip in the stock price recently.

However, it should be noted that this decrease is relatively small and may not have a significant impact on the overall performance of the stock. Axsome Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for central nervous system (CNS) disorders. The company has a strong pipeline of potential treatments for various CNS disorders, including depression, migraines, and Alzheimer’s disease. As the company continues to advance its pipeline and potentially bring new treatments to market, investors may see an increase in the stock price. In conclusion, Mizuho Securities’ reaffirmation of the Outperform rating and the set price target for Axsome Therapeutics is a positive sign for the company and its investors. It reflects confidence in the potential growth of the stock and the potential success of its pipeline treatments. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Axsome Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Axsome Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Axsome Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Axsome Therapeutics are shown below. More…

Analysis

After analyzing the fundamentals of AXSOME THERAPEUTICS, I can confidently say that this company falls under the category of ‘cheetah’ on the Star Chart. This means that while it has achieved high revenue or earnings growth, it is considered less stable due to lower profitability. This is an important aspect for investors to consider when looking at this company. Investors who may be interested in AXSOME THERAPEUTICS are those who are looking for strong growth potential. As a ‘cheetah’ company, AXSOME THERAPEUTICS has shown significant growth in terms of revenue and earnings. This could be attractive to investors who are willing to take on some risk for the potential for high returns. However, it’s important to note that AXSOME THERAPEUTICS also falls in the medium range for asset strength and is weak in terms of dividend and profitability. This means that while the company has strong growth potential, it may not have a solid foundation in terms of its assets and ability to generate profits. This could be a concern for more conservative investors who prioritize stability and consistent returns over high growth potential. Additionally, it’s worth noting that AXSOME THERAPEUTICS has a low health score of 2/10 according to our analysis. This takes into account factors such as cash flow and debt, indicating that the company may struggle to sustain its operations in times of crisis. This could be a red flag for investors who prioritize financial stability and risk management in their investments. Overall, while AXSOME THERAPEUTICS may have strong growth potential, it’s important for investors to carefully consider their risk tolerance and investment goals before deciding to invest in this company. Its classification as a ‘cheetah’ on the Star Chart means it may be more suited for investors who are willing to take on some risk for the potential for high returns, rather than those who prioritize stability and consistent profits. More…

Peers

The company’s lead product candidate, AXS-05, is in Phase III clinical development for treatment-resistant depression (TRD), and has completed Phase II clinical development for Alzheimer’s disease (AD) agitation. Provention Bio Inc, NGM Biopharmaceuticals Inc, Orphazyme AS are all companies focused on developing novel therapies for CNS disorders and are AXS-05’s main competitors in the market.

– Provention Bio Inc ($NASDAQ:PRVB)

Prevention Bio Inc is a clinical-stage biopharmaceutical company developing novel, best-in-class therapeutics for life-threatening infectious diseases with high unmet medical need. The company’s primary focus is on developing its lead product candidate, PB01, for the prevention and treatment of severe sepsis. PB01 is a first-in-class monoclonal antibody that targets a key protein involved in the body’s inflammatory response to infection. Prevention Bio is currently enrolling patients in a Phase 2 clinical trial of PB01 in patients with severe sepsis.

Prevention Bio’s market cap of $643.47 million and ROE of -80.87% reflect the company’s high potential and significant risk. Prevention Bio is a clinical-stage company, meaning its products are still in development and have not yet been approved for market. While the company’s lead product candidate, PB01, has shown promise in early clinical trials, it remains to be seen whether it will be safe and effective in larger trials and ultimately be approved for market. Given the significant risks associated with clinical-stage companies, investors are likely to require a higher return on their investment in Prevention Bio than in more established companies.

– NGM Biopharmaceuticals Inc ($NASDAQ:NGM)

NGM Biopharmaceuticals Inc is a clinical stage biopharmaceutical company. The company focuses on the discovery and development of novel therapeutic proteins for the treatment of serious diseases. NGM Biopharmaceuticals Inc has a market cap of 438.05M as of 2022, a Return on Equity of -28.16%. The company’s main products are in the areas of oncology, diabetes and obesity.

– Orphazyme AS ($OTCPK:OZYMF)

Orphazyme AS is a pharmaceutical company that focuses on the development of treatments for rare diseases. The company has a market cap of 5.56M as of 2022 and a Return on Equity of -845.21%. The company’s focus on rare diseases gives it a niche market, which allows it to charge higher prices for its products. However, the company’s high prices may limit its customer base and its ability to grow its business.

Summary

Mizuho Securities, a leading investment firm, has maintained its bullish stance on Axsome Therapeutics, a biopharmaceutical company focused on developing therapies for central nervous system disorders. This reaffirms the positive sentiment towards Axsome and reflects confidence in the company’s pipeline of promising treatments. Investors should take note of this endorsement by a reputable analyst and consider adding Axsome to their portfolios for potential long-term gains.